|
Podcast: Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer
This expert-led episode of Oncology Data Advisor TM, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine.ain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of adv... |
|
|
Video Viewpoint Strategy Session: Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer
Gain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of advanced endometrial cancer, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine. Start the activity now!
... |
|
|
Podcast: New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia
Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing. Start the activity now.
STATEMENT OF NEED
Chemotherapy-induced neutropenia (CIN) is a potent... |
|
|
Video Viewpoint Strategy Session: New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia
Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing. Start the activity now.
STATEMENT OF NEED
Chemotherapy-induced neutropenia (CIN) is a potent... |
|
MPS II Research Highlights From the WORLDSymposium (Mucopolysaccharidosis type II; MPS II; Hunter syndrome)
This accredited CME activity, led by Barbara Burton, MD, Professor of Pediatrics at Northwestern University Feinberg School of Medicine, highlights the latest research about Mucopolysaccharidosis type II (MPS II; Hunter syndrome) presented at WORLDSymposium 2022 and provides expert analysis of its clinical relevance for busy members of the care team to help them care for patients they may encounter with this rare condition. MPS II, also known as Hunter syndrome, is a rare, progressive lysosoma... |
|
|
Live Webinar: Diagnosis and Evidence-Based Management of T-Cell Lymphoma
Register today for this expert-led discussion presented by Aaron Goodman, MD, Hematologist/Oncologist and Associate Professor of Medicine at UC San Diego Health. This dynamic webinar will provide the latest insights on diagnosing T-cell lymphoma, including subtypes; efficacy and safety data for novel agents; tailoring treatment plans to individual patients; applying strategies to manage symptoms and optimize a patient’s quality of life; and much more!
Don’t miss your chance to enhance y... |
|
|
Video Viewpoint Strategy Session: Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer
This expert-led discussion, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive care plans for adverse events, and optimizing care plans for the survivorship of patients with non–small cell lung cancer. ... |
|
|
Newborn Screening: Talking to Parents
This is the second module in a four-part curriculum focused on Best Practices for Explaining Newborn Screening Results to Parents. This module will focus on how to talk to parents about positive NBS results. |
|
|
Newborn Screening: Metabolic Conditions
This is the third module in a four-part curriculum focused on Best Practices for Explaining Newborn Screening Results to Parents. This module will focus on metabolic diseases which are part of the Recommended Uniform Screening Panel (RUSP) in order to better prepare clinicians to discuss positive results with new parents. |
|
|
Newborn Screening: Hemoglobinopathies and Newer Disorders on the RUSP
This is the fourth module in a four-part curriculum focused on Best Practices for Explaining Newborn Screening Results to Parents. This module will focus on hemoglobinopathies and newer disorders which are part of the Recommended Uniform Screening Panel (RUSP) in order to better prepare clinicians to discuss positive results with new parents. |
|
|
Newborn Screening: From RUSP to Reality
This is the first module in a four-part curriculum focused on Best Practices for Explaining Newborn Screening Results to Parents. This module will provide clinicians with the fundamentals of newborn screening. |
|
|
Research Highlights on Pyruvate Kinase (PK) Deficiency
This accredited CME activity provides a summary of the latest information about Pyruvate kinase (PK) deficiency that was presented at the 2021 American Society of Hematology Annual Meeting (ASH 2021). Since the Covid-19 pandemic limited the ability for specialists to attend ASH 2021 and discuss this latest research, this program provides a review by Rachael Grace, MD, of the most clinically-relevant information on PK deficiency presented during the meeting.
PK deficiency is a rare genetic b... |
|
|
Hereditary Angioedema (HAE) Highlights from ACAAI 2021 Annual Meeting
This accredited CME activity provides a summary of the latest information about hereditary angioedema (HAE) that was presented at the American College of Allergy, Asthma, & immunology 2021 Annual Scientific Meeting (ACAAI 2021). Since the Covid-19 pandemic limited the ability for specialists to attend ACAAI 2021 and discuss this latest research, this program provides an expert review of the most clinically-relevant information on HAE presented during the meeting.
HAE is a rare genetic disea... |
|
|
Lysosomal Storage Diseases: Central Symptoms and Comorbidities
This CME activity highlights how symptoms and comorbidities involving the central nervous system have a key role in how physicians manage patients with lysosomal storage disorders. Key medical problems discussed include cognitive deterioration, behavioral disorders, ophthalmologic problems, neuromuscular deterioration, Parkinson’s disease, depression, and seizures. Newer therapies that allow treatment to cross the blood brain border are also discussed. |
|
Infusing Renewed Hope into Cancer-related Anemia with Intravenous Iron: AN EXPERT-LED EXPLORATION OF RECENT AND EMERGING TRIAL DATA AND CURRENT GUIDELINE RECOMMENDATIONS
Designed and developed to maximize digital audience reach and engagement, this Medical Moments webinar will review all clinically relevant aspects of cancer-related anemia (CRA) management, including chemotherapy-induced anemia (CIA). The activity will begin with a brief primer on iron metabolism and absorption principles, including the practical distinctions between absolute and functional iron deficiency, and the impact of that distinction on treatment approaches. An appraisal of the foundat... |
|
|
New Insights and Avenues for Improved Patient Outcomes in Immune Thrombocytopenia
Gain expert insight on new treatment approaches to improve outcomes for patients with immune thrombocytopenia, including individualized treatment for patients who relapse and strategies to alleviate and improve supportive care. This discussion is led by Howard Liebman, MD, Professor of Medicine and Pathology at the University of Southern California Keck School of Medicine, and Allison Miller lmahiyerobo, MSN, APN, Advanced Practice Nurse at Hematology and Oncology Physicians of Englewood. Star... |
|
Optimal Pharmacologic Treatment of ADPKD: What You Need to Know
This activity consists of three related modules on the pharmacologic management of patients with ADPKD. The modules follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In this 1.5 hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with AD... |
|
|
Paths to Functional Recovery in Major Depressive Disorder: Putting the Patient First A Patient-Centered Approach to Preventing, Detecting, and Managing Adverse Effects of Antidepressants
Adverse effects associated with antidepressants are common. In addition to compromising patients’ health and quality of life, they are one of the most common reasons that individuals with MDD fail to adhere to their treatment plans. To minimize the impact of antidepressant side effects on the lives of patients with MDD, clinicians require education on how to prevent, detect, and manage the most common adverse effects caused by these medications. In this activity, an expert faculty member wil... |
|
|
Paths to Functional Recovery in Major Depressive Disorder: Putting the Patient First Combining Patient-Centered Care for MDD with the Latest Antidepressant Efficacy to Optimize Treatment Plans
Only roughly half of patients with MDD achieve recovery after 6 months of treatment. The others continue to experience residual symptoms that impair their ability to function at work, school, and home. To ensure that more patients with MDD achieve functional recovery, clinicians require practical information about how to provide early, optimized care. In this activity, an expert faculty member will support learners as they are asked to track patients’ response to treatment and detect and man... |
|
|
Implementing the APA Guidelines for the Treatment of Schizophrenia: Caring for the Whole Person
In fall 2020, the American Psychiatric Association (APA) released new practice guidelines for the treatment of patients with schizophrenia. The new guidelines were eagerly awaited, because in the 16 years since the last update, many important discoveries about schizophrenia had been made. An overarching theme in the new APA guidelines is person-centered care. This approach is critical for improving outcomes; currently, as few as 14% to 50% of patients with schizophrenia achieve recovery. Howe... |
|
|
Updates in Myelodysplastic Syndromes: Improving Patient Outcomes
This activity, presented by Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System, will focus on predictive and prognostic markers for myelodysplastic syndromes (MDS), emerging data on novel therapies, and strategies to optimize safety and tolerability for patients with this disease. Start the activity now.
STATEMENT OF NEED
Myelodysplastic syndromes (MDS) comprise a heterogeneous group ofmyeloid malignanciesthat derive from abnormal multipot... |
|
|
Improving Outcomes in Hodgkin Lymphoma
This in-depth discussion, presented by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). Start the activity now.
STATEMENT OF NEED
Hodgkin lymphoma (HL) is a rare malignancy of the lymph nodes and lymphatic system, with about 8,830 new cases diagnosed ... |
|
|
Therapy of B-Cell Acute Lymphoblastic Leukemia: An Evolving Landscape
Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this activity will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. Start the activity now.
STATEMENT OF NEED
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells throughout the bone marrow and blood (Rana... |
|
|
Podcast: Optimizing Management of Metastatic Squamous Non-Small Cell Lung Cancer
Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This activity is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse Practitioner, Abramson Cancer Center. Start the activity now.
STATEMENT OF NEED
Squamous ce... |
|
|
Video Viewpoint Strategy Session: Optimizing Management of Metastatic Squamous Non-Small Cell Lung Cancer
Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This activity is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse Practitioner, Abramson Cancer Center. Start the activity now.
STATEMENT OF NEED
Squamous ce... |
|
|
Expert Perspectives on Practice-Changing Strategies for Improved Patient Outcomes in Multiple Myeloma - Part 2
STATEMENT OF NEED
Multiple myeloma is a B-cell neoplasm characterized by expansion of plasma cells within the bone marrow and extramedullary sites (ACS, 2021). For patients who relapse, treatment becomes increasingly complex, and outcomes worsen with each relapse (Siegal et al, 2020). Advanced multiple myeloma may be associated with considerable disease-related comorbidities in addition to treatment-related adverse events and impaired quality of life, all of which increase the challenges of... |
|
|
Expert Perspectives on Practice-Changing Strategies for Improved Patient Outcomes in Multiple Myeloma - Part 1
STATEMENT OF NEED
Multiple myeloma is a B-cell neoplasm that occurs primarily in older adults. The incidence is expected to rise in conjunction with the aging population. Because symptoms often do not appear until the malignancy is in advanced stages, early diagnosis is difficult, and the 5-year relative survival rate remains only 54% (ACS, 2021). Following diagnosis, management must be guided by cytogenic markers with prognostic significance and correct staging based upon these markers (NC... |
|
Understanding and Managing Nontuberculous Mycobacteria-Lung Disease
This educational module focuses on nontuberculous mycobacterial (NTM) lung disease, its diagnosis, treatment, and patient management. An expert panel discussion, animations, and a patient’s story are highlighted within this education. This EXPLORE module has highly interactive and engaging online content, designed to allow learners to choose their own learning course. |
|
|
New and Emerging Phenotypes in Lysosomal Storage Diseases
This CME activity highlights how modern treatment options for lysosomal storage disorders have created new phenotypes for these once terminal conditions. Understanding the ‘new normal’ for these conditions can help health care providers manage their patients more effectively. |
|
|
Podcast: New Data and Emerging Management Strategies for Migraine Headache
STATEMENT OF NEED
Migraine is a type of chronic headache disorder characterized by headaches of a stabbing, pulsatile quality that last between 4 and 72 hours each, often accompanied by symptoms of nausea and sensitivity to light and noise. An estimated 1.04 billion individuals have been diagnosed with migraine worldwide (Negro et al, 2019). Patients report that migraine impacts virtually every aspect of their lives, including personal relationships, reproductive choices, and productivity i... |
|
|
New Data and Emerging Management Strategies for Migraine Headache
STATEMENT OF NEED
Migraine is a type of chronic headache disorder characterized by headaches of a stabbing, pulsatile quality that last between 4 and 72 hours each, often accompanied by symptoms of nausea and sensitivity to light and noise. An estimated 1.04 billion individuals have been diagnosed with migraine worldwide (Negro et al, 2019). Patients report that migraine impacts virtually every aspect of their lives, including personal relationships, reproductive choices, and productivity i... |
|
|
Applying Precision Medicine in BRAF V600E–Mutant Metastatic Colorectal Cancer
STATEMENT OF NEED
Colorectal cancer is the second leading cause of cancer death among men and women in the United States (ACS,2021). An estimated 149,500 new cases are diagnosed annually, and 52,980 people die of the disease (ACS, 2021). When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because colorectal cancer initially exhibits no symptoms and the use of routine screening is suboptimal, most patients are diagnosed at later stages (ACS, 2021).... |
|
A New Frontier in the Co-Management of Thyroid Eye Disease
Thyroid eye disease, also known as Graves’ orbitopathy, is a potentially serious, progressive autoimmune disease that most often occurs in people with hyperthyroidism, ie, Graves’ disease. Kimberley Cockerham, MD, FACS, moderates this series of six, paired conversations between endocrinologist Terry J. Smith, MD, and eye specialists Wendy W. Lee, MD, and Raymond Douglas, MD, PhD, to explore current and emerging treatment options for thyroid eye disease. In these conversations, faculty revi... |
|
Advanced Ovarian Cancer and PARP Inhibitors: Clinical Insights and Impact on New Data
In this CME activity, Susana M. Campos, MD, MS, MPH, reviews some of the recent clinical developments in the treatment of patients with advanced ovarian cancer with PARP inhibitors. We welcome you to learn more about the updated data from key clinical studies of PARP inhibitor maintenance therapy in advanced ovarian cancer, and the implications of the results on the current and emerging concepts in ovarian cancer clinical practice.
CONTENT AREAS
• Platinum-sensitive recurrent ovarian cance... |
|
|
Video Viewpoint Strategy Session: Optimizing Treatment and Functional Outcomes in Head and Neck Squamous Cell Carcinoma
Gain expert insight on emerging treatment approaches for patients with head and neck squamous cell carcinoma, incuding the safety and tolerabilty of emerging treatments, survivorship care, and much more. This activity is presented by leading experts, Barbara Burtness, MD, Professor of Medicine at Yale School of Medicine and Smilow Cancer Hospital, and Lynsey Teulings, NP, Nurse Practitioner at Yale School of Medicine and Smilow Cancer Hospital. Start the activity now.
STATEMENT OF NEED
H... |
|
|
Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies
Explore best practices in the management of tumor lysis syndrome associated with emerging cancer therapies. This activity, presented by Matthew S. Davids, MD, MMSc, Director of Clinical Research at Dana-Farber Cancer Institute, and Amy Goodrich, RN, BSN, MSN, CRNP-AC, Nurse Practitioner at Johns Hopkins Kimmel Cancer Center, will review plans to optimize prevention, recognition, and treatment, as well as discuss emerging therapies and monitoring strategies for patient care. Start the activity ... |
|
|
Podcast: Update on Immunotherapeutic Strategies for Recurrent and Metastatic Cervical Cancer
In this episode of Oncology Data Advisor TM, learn more about emerging immunotherapies for the treatment of recurrent and metastatic cervical cancer, strategies to monitor and manage adverse events, and developments in the standard of care for patients wth cervical cancer. This activity is presented by leading experts, Bradley Monk, MD, FACS, FACOG, University of Arizona College of Medicine, and Jennifer Filipi, MSN, FNP-C, Massachusetts General Hospital. Listen now!
STATEMENT OF NEED
Th... |
|
|
Video Viewpoint Strategy Session: Update on Immunotherapeutic Strategies for Recurrent and Metastatic Cervical Cancer
Learn more about emerging immunotherapies for the treatment of recurrent and metastatic cervical cancer, strategies to monitor and manage adverse events, and developments in the standard of care for patients wth cervical cancer. This activity is presented by leading experts, Bradley Monk, MD, FACS, FACOG, University of Arizona College of Medicine, and Jennifer Filipi, MSN, FNP-C, Massachusetts General Hospital. Start the activity now!
STATEMENT OF NEED
There are an estimated 13,800 new c... |
|
|
Addressing Challenges in Diagnosis and Treatment of Low-Grade Upper Tract Urothelial Carcinoma
OVERVIEW
Upper tract urothelial carcinoma (UTUC) has many similarities to bladder carcinoma, but also some important differences. Join Dr. Seth Lerner, as he contrasts these 2 diseases, as well as important differences between low-grade and high-grade UTUC. Dr. Lerner highlights important considerations in the instruments, imaging, and biopsy techniques for diagnosing low-grade UTUC. Surgical options are considered, with a focus on patient selection for endoscopic nephron-sparing surgery. The... |
|
|
Clinical Diversity and Genetic Variation in Lysosomal Disorders
Explain the principles of Pathogenic Processes in LSDs.
Explain that lysosomal composition, shape, contents, numbers differ between cell types
and have an effect on disease expression.
Review the evolving understanding of lysosomal autophagy functions. |
|
|
Video ViewPoint Strategy Session: Rethinking the Management of Differentiated and Anaplastic Thyroid Cancers
Gain expert insight and strategies for the management of anaplastic thyroid cancer including emerging data on immunotherapies, and treatment to manage adverse events. This activity is presented by leading experts, Jochen Lorch, MD, MSc, Director Thyroid Cancer Center, Dana-Farber Cancer Institute, and Carolyn Grande, CRNP, AOCNP®, Oncology Nurse Practitioner, Abramson Cancer Center.
STATEMENT OF NEED
Thyroid cancer is one of the most prevalent cancers in the United States. An estimated ... |
|
|
Metastatic Triple-Negative Breast Cancer: Applying Treatment Advances to Personalized Care
Sara A. Hurvitz, MD, FACP, Director of the Breast Cancer Clinical Trials Program at the David Geffen School of Medicine at UCLA, and a prominent authority on TNBC, provides perspectives on personalized care plans for patients with metastatic TNBC, efficacy and safety of emerging treatments, strategies to improve quality of life for patients with metastatic TNBC, and much more! Start the activity now!
STATEMENT OF NEED
With an estimated 284,200 new cases per year, breast cancer is the mo... |
|
|
Exploring Best Practices for Diagnosis and Management of Adult-Onset Stills Disease
Adult-onset Still’s disease (AOSD) is a rare, polygenic autoinflammatory syndrome with a pathogenesis similar to systemic juvenile inflammatory arthritis. Join Drs. Petros Efthimiou and Olga Petryna as they discuss making the diagnosis of AOSD through interpretation of clinical and laboratory findings and careful exclusion of other diseases. The faculty review the evidence related to the variety of medications often used to treat patients with AOSD, focusing on canakinumab, the only medicati... |
|
|
Exploring Best Practices for Diagnosis and Management of Hypereosinophilic Syndrome
Hypereosinophilic syndromes (HESs) are a broad group of disorders that can lead to serious complications, including cardiovascular disease, cerebrovascular disease, and death. Due to their rarity, however, HESs are challenging to diagnose and treat. In this in-depth review, presented by Princess Ogbogu, MD, and developed in collaboration with Michael Wechsler, MD, MMSc, the wide-ranging presentations of HES will be reviewed, along with pathophysiology, classification, and acute and chronic man... |
|
|
Podcast: Novel and Emerging Treatment Strategies for Advanced Classical Hodgkin Lymphoma
Discover new and emerging treatment strategies for advanced classical Hogkin lymphoma, personalized care plans, and best practices for managing supportive care need. This activity is presented by leading experts Kami Maddocks, MD, Professor of Clinical Internal Medicine, Lymphoma Program Director, The James Cancer Hospital at The Ohio State University, and Kelly Brassil, PhD, RN, FAAN, Advanced Practice Nurse, University of Texas MD Anderson Cancer Center. Start the activity now!
STATEMENT ... |
|
|
Video Viewpoint Strategy Session: Novel and Emerging Treatment Strategies for Advanced Classical Hodgkin Lymphoma
Discover new and emerging treatment strategies for advanced classical Hogkin lymphoma, personalized care plans, and best practices for managing supportive care need. This activity is presented by leading experts Kami Maddocks, MD, Professor of Clinical Internal Medicine, Lymphoma Program Director, The James Cancer Hospital at The Ohio State University, and Kelly Brassil, PhD, RN, FAAN, Advanced Practice Nurse, University of Texas MD Anderson Cancer Center. Start the activity now!
STATEMENT ... |
|
|
Acromegaly Highlights from ENDO 2021
This CME activity highlights the latest research about Acromegaly that was presented at ENDO 2021, the annual meeting of the Endocrine Society. This activity provides expert analysis on that research and its clinical relevance for busy members of the care team in order to help them care for patients with acromegaly. |
|
|
From Clinical Trials to Clinical Implications: PARP Inhibitor Combinations in Advanced Prostate Cancer
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with high disease burden and poor outcomes despite androgen deprivation therapy. This activity by Neeraj Agarwal, MD, provides strategies for germline genetic testing and somatic testing to best inform treatment. Poly (ADP-ribose) polymerase (PARP) inhibitor therapy provides a unique approach to treatment. Dr. Agarwal reviews safety and efficacy findings from recent clinical trials for the two PARP inhibitors, o... |
|
|
Resear4ch Developments in Psoriasis
Plaque psoriasis is responsible for a substantial burden on patients, their families, and the healthcare system. To address this burden, important treatment advances continue to be made, including a better understanding of the long-term safety and efficacy of approved medications, as well as the introduction of new classes of medications. Join Steven Feldman, MD, PhD, and Abby Van Voorhees, MD, as they report on research results of these advances presented at the 2021 American Academy of Derma... |
|
|
Strategies for Successfully Diagnosing and Treating Tardive Dyskinesia: Enlisting the Help of Caregivers, Improving the Lives of Patients
At any given time, roughly 1 of every 4 patients taking antipsychotics experiences tardive dyskinesia (TD), a debilitating condition characterized by involuntary movements of the tongue, lips, face, trunk, and extremities. Fortunately, effective pharmacologic treatments for TD are now available. However, it can be challenging for clinicians to assess patients for TD, keep up to date on new agents, and create personalized treatment plans that facilitate long-term treatment success. In this acti... |
|